Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT04166331

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
University Hospital, Limoges (from the registry)
Registry
  • NCT NCT04166331
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04166331. Randomized; triple masking; primary purpose treatment. Start 2020-09-20 (actual); primary completion 2025-07-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
Acronym
ADAPT
Condition
Sepsis
Condition
Cardiomyopathies
Condition
Hypoperfusion
Condition
Left Ventricular Systolic Dysfunction
Intervention (Drug)
Placebos
Intervention (Drug)
Dobutamine
Lead sponsor
University Hospital, Limoges (class: other)
Collaborator
Centre d'Investigation Clinique 1415 (class: not stated)

Record details

Record id
cardio:ct-nct04166331
Content hash
08b9d02a1c1d48e3496a38a203f5dd277bc862f1215a9966f222c7912282c3f0